Internal Medicine

0521779407-19 CUNY1086/Karliner 0 521 77940 7 June 6, 2007 17:50

Systemic Lupus Erythematosus Takayasu Arteritis 1403

■Mycophenolate mofetil:

➣absolute: inability to comply with contraception; cytopenia due

to marrow suppression, life-threatening infection, irreversible

renal disease

➣relative: gastrointestinal side effects

follow-up

Routine

■Every 3–6 months; CBC; BUN, creatinine, and electrolytes; urinalysis;

anti-dsDNA; CH 50 or C3 and C4

■Yearly: bone densitometry with corticosteroid therapy; eye checks

with hydroxychloroquine flow chart for clinical and laboratory

indices of disease activity

■During Treatment of severe organ system involvement: monitor

organ function, drug complications

complications and prognosis

■Drug-induced SLE usually remits when the offending drug is discon-

tinued

■overall survival∼95% at 1 year,∼75% at 10 years

■poorer prognosis in renal disease with elevated creatinine at time of

biopsy, glomerular and tubulointerstitial scarring, initial Hct <26%,

male sex, and black race

■renal allograft survival at 1 year∼70%, at 5 years,∼50%

TAKAYASU ARTERITIS

ERIC L. MATTESON, MD

history & physical

History

■Female:Male 10:1; <40 years of age

Signs & Symptoms

■dizziness, syncope, upper or lower extremity

■claudication

■vascular bruits and pulse deficits

■hypertension more common than in GCA.

tests

n/a